Navidea Biopharmaceuticals (NYSEMKT: NAVB)
Navidea Biopharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Navidea Biopharmaceuticals Company Info
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
News & Analysis
This Week in Biotech: Actions Speak Louder Than Words
Regulatory actions provided the impetus to big moves for these five biotech stocks.
Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower
Navidea shares head the wrong way after a thumbs-up from the FDA.
Why Navidea Biopharmaceuticals Inc. Shares Jumped
Navidea shares soar after announcing an encouraging post-hoc analysis of its phase 3 study involving Lymphoseek. Find out if shares can head even higher.
Why Navidea Biopharmaceuticals, Inc. Shares Jumped
Navidea shares ascend after reporting its fourth-quarter earnings results. Here's the one thing investors should really be watching.
Why Navidea Biopharmaceuticals Inc. Shares Soared
Navidea shares soar after receiving the fast track designation for its lead product. Is now the time to sell or are the good times just getting started?
3 Diagnostic Stocks That May See Sales Soar Because of Obamacare
The implementation of Obamacare could lead to a surge in preventative care diagnostic tests, which would suit these three health care stocks very well.
3 Stocks to Get on Your Watchlist
A once "golden" stock, a promising medical diagnostics company, and a sneaky play in the oil and gas sector top this week's must-adds to your Watchlist.
The 5 Most Misdiagnosed Diseases
Many of us implicitly trust our physicians to be right, but that isn't always the case. Here are the five most commonly misdiagnosed diseases and what might be done to help prevent misdiagnoses in the future.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.